Human recombinant erythropoietin alters the flowdependent vasodilatation of in vitro perfused rat mesenteric arteries with unbalanced endothelial endothelin-1 / nitric oxide ratio

Canadian Journal of Physiology and Pharmacology

Volumn 89, Issue 6, 2011, Pages 435-443

  Barhoumi, Tlili ^a   Jallat, Isabelle ^b   Berthelot, Alain ^b   Laurant, Pascal ^a  

^a UNIVERSITY OF AVIGNON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Bosentan; Culture cells; Endothelin 1; Erythropoietin; L name; Nitric oxide; Shear stress; Vascular flow

Indexed keywords

BOSENTAN; ENDOTHELIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTERY CATHETERIZATION; ARTERY ENDOTHELIUM; ARTERY PERFUSION; ARTERY TONE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; IN VITRO STUDY; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SHEAR STRESS; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL LINE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HEMATINICS; HUMANS; MALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; RECOMBINANT PROTEINS; SULFONAMIDES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 79960833698     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/y11-032     Document Type: Article

References (45)

1. Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E.S., Kessimian, N., and Noguchi, C.T. 1994. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U.S. A. 91(9): 3974-3978. doi:10.1073/pnas.91.9.3974.
2. Banerjee, D., Rodriguez, M., Nag, M., and Adamson, J.W. 2000. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int. 57(5): 1895-1904. doi:10.1046/j.1523-1755.2000.00039.x.
3. Barhoumi, T., Kasal, D.A., Li, M.W., Shbat, L., Laurant, P., Neves, M.F., et al. 2011. T regulatory lymphocytes prevent angiotensin Iinduced hypertension and vascular injury. Hypertension, 57(3): 469-476. doi:10.1161/HYPERTENSIONAHA.110.162941.
4. Bergaya, S., Matrougui, K., Meneton, P., Henrion, D., and Boulanger, C.M. 2004. Role of tissue kallikrein in response to flow in ouse resistance arteries. J. Hypertens. 22(4): 745-750. doi:10.1097/ 00004872-200404000-00017.
5. Berglund, B., and Ekblom, B. 1991. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J. Intern. Med. 229(2): 125-130. doi:10.1111/j.1365-2796.1991.tb00319.x.
6. Bertinieri, G., Parati, G., Ulian, L., Santucciu, C., Massaro, P., Cosentini, R., et al. 1998. Hemodilution reduces clinic and ambulatory blood pressure in polycythemic patients. Hypertension, 31(3): 848-853.
7. Bode-Böger, S.M., Böger, R.H., Kuhn, M., Radermacher, J., and Frölich, J.C. 1996. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 50(4): 1255-1261. doi:10.1038/ki.1996.435.
8. Boulanger, C., and Luscher, T.F. 1990. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85(2): 587-590. doi:10.1172/JCI114477.
9. Bruneval, P., Sassy, C., Mayeux, P., Belair, M.F., Casadevall, N., Roux, F.X., et al. 1993. Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis. Blood, 81 (6): 1593-1597.
10. Carlini, R.G., Dusso, A.S., Obialo, C.I., Alvarez, U.M., and Rothstein, M. 1993. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 43(5): 1010-1014. doi:10.1038/ki.1993.142.
11. Dhaun, N., Goddard, J., and Webb, D.J. 2006. The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 17(4): 943-955. doi:10.1681/ASN.2005121256.
12. Edgell, C.J., McDonald, C.C., and Graham, J.B. 1983. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. U.S.A. 80(12): 3734-3737. doi:10.1073/pnas.80.12.3734.
13. Engert, A. 2005. Recombinant human erythropoietin in oncology: current status and further developments. Ann. Oncol. 16(10): 1584-1595. doi:10.1093/annonc/mdi307.
14. Groenendijk, B.C., Van der Heiden, K., Hierck, B.P., and Poelmann, R.E. 2007. The role of shear stress on ET-1, KLF2, and NOS-3 expression in the developing cardiovascular system of chicken embryos in a venous ligation model. Physiology (Bethesda), 22 (22): 380-389.
15. Hosoya, T., Maruyama, A., Kang, M.I., Kawatani, Y., Shibata, T., Uchida, K., et al. 2005. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J. Biol. Chem. 280(29): 27244-27250. doi:10.1074/jbc. M502551200.
16. Juvonen, E., Ikkala, E., Fyhrquist, F., and Ruutu, T. 1991. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood, 78(11): 3066-3069.
17. Katoh, K., Mizuno, K., Hashimoto, S., Okazaki, K., Asahi, K., Kuriki, M., et al. 1994. Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci. 54 (16): PL253-PL259.
18. Koller, A., Sun, D., and Kaley, G. 1993. Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ. Res. 72(6): 1276-1284.
19. Lacasse, M.S., Kingma, I., Larivière, R., Grose, J.H., and Lebel, M. 1997. Uremia enhances the blood pressure response to erythropoietin. Clin. Exp. Hypertens. 19(4): 389-401.
20. Larivière, R., and Lebel, M. 2003. Endothelin-1 in chronic renal failure and hypertension. Can. J. Physiol. Pharmacol. 81(6): 607-621. doi:10.1139/y03-012.
21. Laughlin, M.H., Newcomer, S.C., and Bender, S.B. 2008. Importance of hemodynamic forces as signals for exercise-induced changes in endothelial cell phenotype. J. Appl. Physiol. 104(3): 588-600. doi:10.1152/japplphysiol.01096.2007.
22. Laurant, P., Touyz, R.M., and Schiffrin, E.L. 1997. Effect of pressurization on mechanical properties of mesenteric small arteries from spontaneously hypertensive rats. J. Vasc. Res. 34 (2): 117-125.
23. Malek, A.M., Zhang, J., Jiang, J., Alper, S.L., and Izumo, S. 1999. Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J. Mol. Cell. Cardiol. 31(2): 387-399. doi:10.1006/jmcc.1998.0873.
24. McFarlane, P.A., Pisoni, R.L., Eichleay, M.A., Wald, R., Port, F.K., and Mendelssohn, D. 2010. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 78 (2): 215-223. doi:10.1038/ki.2010.108.
25. Meziri, F., Binda, D., Touati, S., Pellegrin, M., Berthelot, A., Touyz, R.M., and Laurant, P. 2011. Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin. Eur. J. Appl. Physiol. [doi.] doi:10.1007/s00421-011-1829-z.
26. Moreno, F., Sanz-Guajardo, D., Lopez-Gomez, J.M., Jofre, R., and Valderrabano, F.Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. 2000. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J. Am. Soc. Nephrol. 11(2): 335-342.
27. Nagai, T., Akizawa, T., Nakashima, Y., Kohjiro, S., Nabeshima, K., Kanamori, N., et al. 1995. Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol. Dial. Transplant. 10(10): 1814-1819.
28. Ni, Z., Wang, X.Q., and Vaziri, N.D. 1998. Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade. Hypertension, 32(4): 724-729.
29. Ohura, N., Yamamoto, K., Ichioka, S., Sokabe, T., Nakatsuka, H., Baba, A., et al. 2003. Global analysis of shear stress-responsive genes in vascular endothelial cells. J. Atheroscler. Thromb. 10(5): 304-313.
30. Pyke, K.E., and Tschakovsky, M.E. 2005. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J. Physiol. 568(2): 357-369. doi:10.1113/jphysiol.2005.089755.
31. Quaschning, T., Ruschitzka, F., Stallmach, T., Shaw, S., Morawietz, H., Goettsch, W., et al. 2003. Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J. 17(2): 259-261.
32. Raine, A.E. 1988. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet, 1(8577): 97-100. doi:10.1016/S0140-6736(88)90293-0.
33. Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell'Era, P., et al. 1999. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 93(8): 2627-2636.
34. Richard, V., Hogie, M., Clozel, M., Loffler, B.M., and Thuillez, C. 1995. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation, 91(3): 771-775.
35. Rodrigue, M.E., Brochu, I., D'orléans-Juste, P., Larivièrea, R., and Lebel, M. 2008. Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system. Am. J. Hypertens. 21(6): 639-643. doi:10.1038/ajh.2008.37.
36. Ruschitzka, F.T., Wenger, R.H., Stallmach, T., Quaschning, T., de Wit, C., Wagner, K., et al. 2000. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. U.S.A. 97(21): 11609-11613. doi:10.1073/pnas.97.21.11609.
37. Santolaya, R.B., Lahiri, S., Alfaro, R.T., and Schoene, R.B. 1989. Respiratory adaptation in the highest inhabitants and highest Sherpa mountaineers. Respir. Physiol. 77(2): 253-262. doi:10. 1016/0034-5687(89)90011-X.
38. Schiffrin, E.L., Lipman, M.L., and Mann, J.F. 2007. Chronic kidney disease: effects on the cardiovascular system. Circulation, 116(1): 85-97. doi:10.1161/CIRCULATIONAHA.106.678342.
39. Shimada, N., Saka, S., Sekizuka, K., Tanaka, A., Takahashi, Y., Nakamura, T., et al. 2003. Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients. Ren. Fail. 25(4): 569-578. doi:10.1081/JDI- 120022548.
40. Smith, K.J., Bleyer, A.J., Little, W.C., and Sane, D.C. 2003. The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59(3): 538-548. doi:10.1016/S0008-6363(03)00468-1.
41. Takamura, Y., Shimokawa, H., Zhao, H., Igarashi, H., Egashira, K., and Takeshita, A. 1999. Important role of endothelium-derived hyperpolarizing factor in shear stress-induced endotheliumdependent relaxations in the rat mesenteric artery. J. Cardiovasc. Pharmacol. 34(3): 381-387. doi:10.1097/00005344-199909000- 00010.
42. Topper, J.N., Cai, J., Falb, D., and Gimbrone, M.A., Jr. 1996. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U.S.A. 93(19): 10417-10422. doi:10.1073/pnas. 93.19.10417.
43. Vogel, J., Kiessling, I., Heinicke, K., Stallmach, T., Ossent, P., Vogel, O., et al. 2003. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity. Blood, 102(6): 2278-2284. doi:10.1182/blood-2003-01-0283.
44. Wang, X.Q., and Vaziri, N.D. 1999. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. ypertension, 33(3): 894-899.
45. Ziegler, T., Silacci, P., Harrison, V.J., and Hayoz, D. 1998. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension, 32(2): 351-355.